-
Innovation Ranking
NewInnovation Ranking – Curis Inc
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries. The company has four drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-151 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Triple-Negative Breast Cancer (TNBC) Drug Details: AMT-151 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sabatolimab in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Gastric Cancer Drug Details: Emavusertib hydrochloride is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Esophageal Cancer Drug Details: Emavusertib hydrochloride is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Secondary CNS Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Secondary CNS Lymphoma Drug Details: Emavusertib hydrochloride is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Refractory Acute Myeloid Leukemia Drug Details: Emavusertib hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Emavusertib Hydrochloride in Relapsed Acute Myeloid Leukemia Drug Details: Emavusertib hydrochloride is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Sleep Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Sleep Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Sleep Disorders Drug Details: Brexanolone is under development for...